Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up

Dimethyl fumarate (DMF) and fingolimod (FTY) are approved oral disease modifying therapies (DMTs) for relapsing multiple sclerosis (MS). There are currently no known head-to-head studies comparing DMF and FTY over 36  months, which leaves their relative effectiveness unknown.

Source: Journal of the Neurological Sciences - October 14, 2019 Category: Neurology Authors: Brandi Vollmer, Daniel Ontaneda, Haleigh Harris, Kavita Nair, Robert A. Bermel, John R. Corboy, Robert J. Fox, Timothy Vollmer, Jeffrey A. Cohen, Enrique Alvarez, Carrie M. Hersh Source Type: research